menu
    • menu
    [{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Senaparib","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Senaparib","moa":"PARP","graph1":"Oncology","graph2":"Approved FDF","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IMPACT Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"IMP9064","moa":"||ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Burning Rock Dx","highestDevelopmentStatusID":"5","companyTruncated":"IMPACT Therapeutics, Inc \/ Burning Rock Dx"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Dingxin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Senaparib","moa":"PARP","graph1":"Oncology","graph2":"Phase III","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Dingxin Capital","highestDevelopmentStatusID":"10","companyTruncated":"IMPACT Therapeutics, Inc \/ Dingxin Capital"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"IMPACT Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Senaparib","moa":"PARP","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ IMPACT Therapeutics, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ IMPACT Therapeutics, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Senaparib

    Menu

    Senaparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IMPACT Therapeutics, Inc

                            China arrow
                            EASL Congress
                            Not Confirmed

                            IMPACT Therapeutics, Inc

                            China arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Senaparib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

                            Details : Paxonin (senaparib) is a PARP 1/2 inhibitor, received NMPA approval as monotherapy for adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian cancer.

                            Product Name : Paxonin

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 16, 2025

                            Lead Product(s) : Senaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanghai Junshi Biosciences

                            China arrow
                            EASL Congress
                            Not Confirmed

                            Shanghai Junshi Biosciences

                            China arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Senaparib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : IMPACT Therapeutics, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IMPACT Therapeutics Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Trea...

                            Details : IMP4927 (senaparib) is a PARP inhibitor, being investigated as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved complete response or partial response.

                            Product Name : IMP4927

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 04, 2023

                            Lead Product(s) : Senaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : IMPACT Therapeutics, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IMPACT Therapeutics, Inc

                            China arrow
                            EASL Congress
                            Not Confirmed

                            IMPACT Therapeutics, Inc

                            China arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Senaparib,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC

                            Details : The preliminary clinical results for a phase I b/II study investigating the PARP inhibitor IMP4297 having Senaparib in combination with temozolomide (TMZ) for the treatment of advanced solid tumors.

                            Product Name : IMP4297

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 19, 2022

                            Lead Product(s) : Senaparib,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IMPACT Therapeutics, Inc

                            China arrow
                            EASL Congress
                            Not Confirmed

                            IMPACT Therapeutics, Inc

                            China arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Senaparib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Dingxin Capital

                            Deal Size : Undisclosed

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Impact Therapeutics Announces Completion of Series D1 Financing

                            Details : Proceeds will be used to accelerate the development of its synthetic lethality programs, including IMP4297, which are showing best-in-class potential. The company already has three synthetic lethality compounds in the clinical stage.

                            Product Name : IMP4297

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 14, 2022

                            Lead Product(s) : Senaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Dingxin Capital

                            Deal Size : Undisclosed

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IMPACT Therapeutics, Inc

                            China arrow
                            EASL Congress
                            Not Confirmed

                            IMPACT Therapeutics, Inc

                            China arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMP9064,Senaparib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Burning Rock Dx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in Both U...

                            Details : Under the collaboration, Burning Rock will provide the testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, with worldwide intellectual property rights.

                            Product Name : IMP9064

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 11, 2021

                            Lead Product(s) : IMP9064,Senaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Burning Rock Dx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth